Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease ...
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...
A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched. The technology has largely been tested in cells ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Racism that fueled the syphilis study still permeates the U.S. health care system, causing disparities in access to medical ...
Dive into The Register's online archive of incisive tech news reporting, features, and analysis dating back to 1998 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results